Navigation Links
Genomenon Accelerates Rare and Genetic Disease Research with Mastermind v2.0
Date:11/6/2019

Genomenon® announced the release of Mastermind® version 2.0 today. The Genomic Search Engine now includes the ability to search the entirety of the genomic literature by phenotypes (symptoms). This new functionality will further accelerate diagnosis of patients with genetic and rare diseases.

Patients, particularly those with rare diseases, don’t always have a name for their condition. This makes it very difficult to diagnose and treat their disease. The ability to search the genetic literature by symptoms (following the Human Phenotype Ontology, or HPO) helps clinicians narrow their diagnosis to the appropriate disease and treatment.

Genomenon’s Mastermind Genomic Search Engine is the world’s largest and most complete source of genomic evidence. Doctors and researchers use Mastermind to find the scientific evidence relevant to their patients’ DNA profile for diagnostic and therapeutic recommendations. The new release of Mastermind includes a more streamlined search function to help doctors more quickly scour through the millions of research articles to find cases that match their patients’ genomic profile and symptoms.

The ability to search by phenotype was the top feature requested by the children’s hospitals and genetic testing labs that use Mastermind for variant interpretation. A preview of the new version was well received at the American Society for Human Genetics annual meeting in October.

"We are world-renowned for the speed of our WGS (whole genome sequencing) interpretations, and using Mastermind has been a crucial step in accelerating our progress." said Shareef Nahas, Senior Director of Clinical Operations for Rady Children's Institute for Genomic Medicine. "This new functionality will be invaluable in our ongoing work to diagnose and treat babies with rare diseases."

“The ability to search by phenotype gives Mastermind users even more power to discover which genes in a patient’s DNA are most likely to be relevant based on empirical data in the medical literature.” Said Dr. Mark Kiel, co-founder and Chief Science Officer of Genomenon.

About Genomenon

Genomenon connects patient DNA with the billions of dollars spent on research to help doctors diagnose and cure cancer patients and babies with rare diseases. Our flagship product, the Mastermind Genomic Search Engine is used by hundreds of genetic labs worldwide to accelerate diagnosis, increase diagnostic yield and assure repeatability in reporting genetic testing results. We license our Mastermind Curated Genomic Datasets to pharmaceutical and bio-pharma companies to inform precision medicine development, deliver genomic biomarkers for clinical trial target selection, and support CDx regulatory submissions with empirical evidence.

For more information, visit Genomenon.com.

Read the full story at https://www.prweb.com/releases/genomenon_accelerates_rare_and_genetic_disease_research_with_mastermind_v2_0/prweb16701259.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. The China National Genebank accelerates growth by a strategic alliance with BioStorage Technologies
2. Fragmented sleep accelerates cancer growth
3. Study finds climate change accelerates hybridization between native, invasive trout
4. Genetic circuit allows both individual freedom, collective good
5. Epigenetic changes shed light on biological mechanism of autism
6. Europe needs genetically engineered crops, scientists say
7. Genetics Society of Americas GENETICS journal highlights for May 2013
8. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
9. Genetic and clinical factors best to predict late recurrence in estrogen receptor POS breast cancer
10. Fred Hutch evolutionary geneticist Harmit Malik selected as an HHMI investigator
11. Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2019)... ... , ... Since 2010, The HOTH has served over 200,000 businesses with awesome ... clients, they’ve earned a place on the highly-competitive and desirable Inc. 5,000 List of ... and accolades along the way. , Now, The HOTH is ready to ...
(Date:10/26/2019)... ... October 23, 2019 , ... ... nanotube surface that demonstrated the FDA requirements for nanotechnology. , “We are ... This nanotechnology plays an important role in achieving Nanovis’ goal to reduce the ...
(Date:10/26/2019)... , ... October 24, 2019 , ... THE PRINCESS VEST, ... been the standard choice for female providers, they were the only choice. Women in ... breasts, or a loose garment that can allow harmful radiation to penetrate the sides ...
Breaking Biology News(10 mins):
(Date:11/2/2019)... ... October 31, 2019 , ... Join Patrick Raber, PhD, Manager, ... webinar on Friday, November 15, 2019 at 1pm EST to learn about ... profiling T-cell receptors (TCRs) and B-cell receptors (BCRs), has been widely utilized to ...
(Date:10/30/2019)... (PRWEB) , ... October 30, 2019 , ... While using ... researchers and students at South Dakota School of Mines & Technology are ... while leaving healthy cells alive. , If successful, the technique would prove to ...
(Date:10/29/2019)... ... , ... CaroGen Corporation , a biotechnology company, today announced three distinguished ... R Wands, MD, of Brown University , Dr. Steve Projan, PhD, FAAM, ... PhD, of Wayne State University, formerly a professor at Yale University School of Medicine ...
(Date:10/29/2019)... NEWTON, Mass. (PRWEB) , ... October 29, 2019 ... ... the spectral signature of the skin*. Using Silios CMS-C multispectral imagers , ... This new approach can replace identification based on retinal imaging, face recognition, fingerprints ...
Breaking Biology Technology: